NCT03641313 2026-04-13Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction CancerNational Cancer Institute (NCI)Phase 2 Active not recruiting17 enrolled 14 charts